AB Science reveals masitinib data in ALS trial

Newly released data from a Phase II/III trial suggested that the higher of two doses of masitinib (AB1010) from AB Science S.A. (Euronext:AB) significantly slowed the progression of amyotrophic lateral sclerosis vs. placebo in a subgroup of patients with more slowly progressing disease at baseline, but did not significantly separate from placebo in a broader patient population.

In September 2016, the company submitted an MAA to EMA for masitinib to treat ALS. It expects a decision in 4Q17. The company did not respond to an inquiry from BioCentury regarding the specific patient population for which it is seeking approval...